Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis. J of Skin [Internet]. 2024 Jan. 16 [cited 2025 May 17];8(1):s313. Available from: https://skin.dermsquared.com/skin/article/view/2391